VESICARE SIDE EFFECTS

  • Generic Name: solifenacin succinate
  • Brand Name: VESIcare
  • Drug Class: Anticholinergics, Genitourinary
Last updated on MDtodate: 10/11/2022

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VESIcare has been evaluated for safety in 1811 patients in randomized, placebo-controlled trials. Expected adverse reactions of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The incidence of dry mouth and constipation in patients treated with VESIcare was higher in the 10 mg compared to the 5 mg dose group.

In the four 12-week double-blind clinical trials, severe fecal impaction, colonic obstruction, and intestinal obstruction were reported in one patient each, all in the VESIcare 10 mg group. Angioneurotic edema has been reported in one patient taking VESIcare 5 mg. Compared to 12 weeks of treatment with VESIcare, the incidence and severity of adverse reactions were similar in patients who remained on drug for up to 12 months.

The most frequent adverse reaction leading to study discontinuation was dry mouth (1.5%). Table 1 lists the rates of identified adverse reactions, derived from all reported adverse events, in randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with VESIcare 5 or 10 mg once daily for up to 12 weeks.

Table 1: Percentages of Patients with Identified Advers e Reactions , Derived from All Advers e Events Exceeding Placebo Rate and Reported by 1% or More Patients for Combined Pivotal Studies

Placebo (%) VESIcare 5 mg (%) VESIcare 10 mg (%)
Number of Patients 1216 578 1233
GASTROINTESTINAL DISORDERS
Dry Mouth 4.2 10.9 27.6
Constipation 2.9 5.4 13.4
Nausea 2.0 1.7 3.3
Dyspepsia 1.0 1.4 3.9
Abdominal Pain Upper 1.0 1.9 1.2
Vomiting NOS 0.9 0.2 1.1
INFECTIONS AND INFESTATIONS
Urinary T ract Infection NOS 2.8 2.8 4.8
Influenza 1.3 2.2 0.9
Pharyngitis NOS 1.0 0.3 1.1
NERVOUS SYSTEM DISORDERS
Dizziness 1.8 1.9 1.8
EYE DISORDERS
Vision Blurred 1.8 3.8 4.8
Dry Eyes NOS 0.6 0.3 1.6
RENAL AND URINARY DISORDERS
Urinary Retention 0.6 0 1.4
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
Edema Lower Limb 0.7 0.3 1.1
Fatigue 1.1 1.0 2.1
PSYCHIATRIC DISORDERS
Depression NOS 0.8 1.2 0.8
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Cough 0.2 0.2 1.1
VASCULAR DISORDERS
Hypertension NOS 0.6 1.4 0.5

 

Post-Marketing Experience

Because these spontaneously reported events are from the worldwide postmarketing experience, the frequency of events and the role of solifenacin in their causation cannot be reliably determined.

The following events have been reported in association with solifenacin use in worldwide postmarketing experience:

General: peripheral edema, hypersensitivity reactions, including angioedema with airway obstruction, rash, pruritus, urticaria, and anaphylactic reaction;

Central Nervous: headache, confusion, hallucinations, delirium and somnolence;

Cardiovascular: QT prolongation; Torsade de Pointes, atrial fibrillation, tachycardia, palpitations;

Hepatic: liver disorders mostly characterized by abnormal liver function tests, AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma-glutamyl transferase);

Renal: renal impairment;

Metabolism and nutrition disorders: decreased appetite, hyperkalemia;

Dermatologic: exfoliative dermatitis and erythema multiforme;

Eye disorders: glaucoma;

Gastrointestinal disorders: gastroesophageal reflux disease and ileus;

Respiratory, thoracic and mediastinal disorders: dysphonia;

Musculoskeletal and connective tissue disorders: muscular weakness.

 

SRC: NLM .